DATA GRAPHICS | Data Byte
Kesimpta gains but Ocrevus still dominates MS sales
CD20 class gains market share as other mechanisms’ sales flatten or decline
April 27, 2023 8:32 PM UTC
Kesimpta is the only other multiple sclerosis drug showing strong growth as Ocrevus continues to dominate the market.
Ocrevus ocrelizumab from Roche (SIX:ROG; OTCQB:RHHBY) remained the top-selling MS drug in 1Q23, netting CHF1.6 billion ($1.8 billion) in the quarter. Across eight other branded therapies, seven had declining revenue quarter-over-quarter, including the entire MS franchise of Biogen Inc. (NASDAQ:BIIB). This week, CEO Chris Viehbacher took his first major steps in resizing Biogen’s cost base and decreasing pipeline risk...
BCIQ Target Profiles